← Back to Clinical Trials
Recruiting NCT07293949

NCT07293949 Ultrasonographic Evaluation of Talar Cartilage Thickness in Patients With Spinal Cord Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07293949
Status Recruiting
Phase
Sponsor Gaziosmanpasa Research and Education Hospital
Condition Spinal Cord Injuries (SCI)
Study Type OBSERVATIONAL
Enrollment 76 participants
Start Date 2025-12-20
Primary Completion 2026-02

Trial Parameters

Condition Spinal Cord Injuries (SCI)
Sponsor Gaziosmanpasa Research and Education Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 76
Sex ALL
Min Age 18 Years
Max Age 60 Years
Start Date 2025-12-20
Completion 2026-02

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Spinal cord injury patients often present with musculoskeletal comorbidities, including osteoarthritis. Early detection of cartilage damage is important for preventing osteoarthritis progression. This study aims to compare the talar cartilage thicknesses of spinal cord injury patients with healthy subjects. The secondary aim is to investigate a correlation between the talar cartilage thickness and disease-related parameters. The patient group is to be assessed for talar cartilage thickness (via ultrasound), functional status, spasticity, and ambulation levels.

Eligibility Criteria

Inclusion Criteria: * Aged between 18 to 60 years, * Cervical, thoracal or lumber level of spinal cord injury * AIS (American Spinal Injury Association Impairment Scale) Level A, B, C, or D * Assisted ambulation of any kind * Literacy * Giving oral and written consent to participate in the study Exclusion Criteria: * Patients with sacral level injury * AIS E * MAS 4 level of spasticity * History of any lower extremity operation * History of fracture * Botulinum toxin injection in the last 6 months * Existing diagnosis of any rheumatologic or endocrine diseases

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology